AR053326A1 - 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. - Google Patents
4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende.Info
- Publication number
- AR053326A1 AR053326A1 ARP060100092A ARP060100092A AR053326A1 AR 053326 A1 AR053326 A1 AR 053326A1 AR P060100092 A ARP060100092 A AR P060100092A AR P060100092 A ARP060100092 A AR P060100092A AR 053326 A1 AR053326 A1 AR 053326A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- hydrogen
- cycloalkyl
- alkyl
- zero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los medicamentos que comprenden compuestos de este tipo son utiles en la prevencion o el tratamiento de diversos trastornos. Por ejemplo, los compuestos se pueden utilizar, inter alia, en el evento de trastornos renales, tales como insuficiencia renal aguada o cronica, en el evento de trastornos de la funcion biliar y en el evento de trastornos respiratorios tales como ronquidos o apneas del sueno. Se proveen también composiciones farmacéuticas que contienen a éstos compuestos como principio activo. Reivindicacion 1: Un compuesto de la formula (1) en donde R1, R2, R3 y R4 son cada uno, de manera independiente, hidrogeno, F, Cl, Br, I, CN, NO2 o R11-(CmH2m)-An-; m es cero, 1, 2, 3, o 4; n es cero o 1; R11 es hidrogeno, metilo o CpF2p+1; A es oxígeno, NH, N(CH3) o S(O)q; p es 1, 2 o 3; q es cero,1 o 2; R5 es hidrogeno, alquilo con 1, 2, 3, 4, 5 o 6 átomos de cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R6 es hidrogeno, OH, F, CF3, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3,4 5 o 6 átomos de carbono; R7 y R8 son cada uno, de manera independiente, hidrogeno F, Cl, Br, CN, CO2R12, NR13R14 o R16-(CmmH2mm)-Bnn-; R12 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono, cicloalquilo con 3, 4, 5 0 6 átomos de carbono; R13 y R14 son cada uno, de manera independiente, hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R13 y R14 con el átomo de nitrogeno al que están unidos forman un anillo de 4, 5, 6 o 7 miembros en donde un grupo CH2 puede estar reemplazado por NR15, S u oxígeno; R15 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; mm es cero, 1, 2, 3 o 4; nn es cero o 1; R16 es oxígeno o S(O)qq; pp es 1, 2 o 3; qq es cero, 1 o 2; W es CrH3r o CsJ2S-2; en donde cada uno o varios grupos CH2 en CrH2r y CsH2s-2 pueden estar reemplazados por NR17, oxígeno o S; R17 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3,4, 5 o 6 átomos de carbono; r es 1, 2, 3, 4, 5, 6, 7 u 8; s es 2, 3, 4,5,6,7 u 8; x es -C(O)-o -S(O)2-; Z es -C(O)- o un enlace; y también sus sales trifuoroacetatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005001411A DE102005001411A1 (de) | 2005-01-12 | 2005-01-12 | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053326A1 true AR053326A1 (es) | 2007-05-02 |
Family
ID=36121409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100092A AR053326A1 (es) | 2005-01-12 | 2006-01-10 | 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. |
Country Status (31)
Country | Link |
---|---|
US (1) | US7868003B2 (es) |
EP (1) | EP1838315B1 (es) |
JP (1) | JP2008526906A (es) |
KR (1) | KR20070094916A (es) |
CN (1) | CN101184488A (es) |
AR (1) | AR053326A1 (es) |
AU (1) | AU2005324833A1 (es) |
BR (1) | BRPI0519854A2 (es) |
CA (1) | CA2594419A1 (es) |
CR (1) | CR9191A (es) |
DE (1) | DE102005001411A1 (es) |
DK (1) | DK1838315T3 (es) |
DO (1) | DOP2006000011A (es) |
ES (1) | ES2470980T3 (es) |
GT (1) | GT200600017A (es) |
IL (1) | IL184314A0 (es) |
MA (1) | MA29227B1 (es) |
MX (1) | MX2007008269A (es) |
MY (1) | MY142493A (es) |
NI (1) | NI200700162A (es) |
NO (1) | NO20074084L (es) |
NZ (1) | NZ556080A (es) |
PA (1) | PA8659501A1 (es) |
PT (1) | PT1838315E (es) |
RU (1) | RU2398766C2 (es) |
TN (1) | TNSN07263A1 (es) |
TW (1) | TW200637842A (es) |
UA (1) | UA88941C2 (es) |
UY (1) | UY29333A1 (es) |
WO (1) | WO2006074813A1 (es) |
ZA (1) | ZA200704728B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110050718A (ko) * | 2008-09-02 | 2011-05-16 | 사노피-아벤티스 | 치환된 아미노인단 및 그의 유사체, 및 그의 제약 용도 |
CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
BR112012015868A2 (pt) | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
WO2012151559A2 (en) * | 2011-05-05 | 2012-11-08 | Rose Pharmaceuticals, Llc | Cytotoxic therapy by proton flux modulation |
KR20230132619A (ko) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
SG11201700398RA (en) * | 2014-07-25 | 2017-02-27 | Taisho Pharmaceutical Co Ltd | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl |
JP6903923B2 (ja) * | 2016-01-22 | 2021-07-14 | 大正製薬株式会社 | ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬 |
AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19633966A1 (de) | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
CN100436420C (zh) | 1999-11-03 | 2008-11-26 | Amr科技公司 | 4-苯基取代的四氢异喹啉及其用于制备药物的用途 |
DE19960204A1 (de) | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
PT1453810E (pt) * | 2001-12-05 | 2009-05-27 | Sanofi Aventis Deutschland | 4-feniltetra-hidroisoquinolinas substituídas, processo para a sua preparação, sua utilização como medicamento, bem como medicamento contendo as mesmas |
DE10163914A1 (de) | 2001-12-22 | 2003-07-03 | Aventis Pharma Gmbh | Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
-
2005
- 2005-01-12 DE DE102005001411A patent/DE102005001411A1/de not_active Withdrawn
- 2005-12-30 EP EP05823573.0A patent/EP1838315B1/de active Active
- 2005-12-30 CN CNA2005800465296A patent/CN101184488A/zh active Pending
- 2005-12-30 ES ES05823573.0T patent/ES2470980T3/es active Active
- 2005-12-30 UA UAA200709180A patent/UA88941C2/ru unknown
- 2005-12-30 DK DK05823573.0T patent/DK1838315T3/da active
- 2005-12-30 WO PCT/EP2005/014127 patent/WO2006074813A1/de active Application Filing
- 2005-12-30 NZ NZ556080A patent/NZ556080A/en not_active IP Right Cessation
- 2005-12-30 MX MX2007008269A patent/MX2007008269A/es active IP Right Grant
- 2005-12-30 AU AU2005324833A patent/AU2005324833A1/en not_active Abandoned
- 2005-12-30 RU RU2007130706/04A patent/RU2398766C2/ru not_active IP Right Cessation
- 2005-12-30 PT PT58235730T patent/PT1838315E/pt unknown
- 2005-12-30 CA CA002594419A patent/CA2594419A1/en not_active Abandoned
- 2005-12-30 BR BRPI0519854-2A patent/BRPI0519854A2/pt not_active IP Right Cessation
- 2005-12-30 KR KR1020077015974A patent/KR20070094916A/ko not_active Application Discontinuation
- 2005-12-30 JP JP2007550712A patent/JP2008526906A/ja not_active Abandoned
-
2006
- 2006-01-10 AR ARP060100092A patent/AR053326A1/es not_active Application Discontinuation
- 2006-01-10 TW TW095100824A patent/TW200637842A/zh unknown
- 2006-01-11 GT GT200600017A patent/GT200600017A/es unknown
- 2006-01-11 PA PA20068659501A patent/PA8659501A1/es unknown
- 2006-01-11 MY MYPI20060103A patent/MY142493A/en unknown
- 2006-01-12 DO DO2006000011A patent/DOP2006000011A/es unknown
- 2006-01-12 UY UY29333A patent/UY29333A1/es unknown
-
2007
- 2007-06-14 ZA ZA200704728A patent/ZA200704728B/en unknown
- 2007-06-19 CR CR9191A patent/CR9191A/es not_active Application Discontinuation
- 2007-06-21 NI NI200700162A patent/NI200700162A/es unknown
- 2007-07-01 IL IL184314A patent/IL184314A0/en unknown
- 2007-07-06 MA MA30050A patent/MA29227B1/fr unknown
- 2007-07-11 US US11/776,041 patent/US7868003B2/en not_active Expired - Fee Related
- 2007-07-11 TN TNP2007000263A patent/TNSN07263A1/en unknown
- 2007-08-07 NO NO20074084A patent/NO20074084L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GT200600017A (es) | 2006-08-28 |
RU2007130706A (ru) | 2009-02-20 |
TNSN07263A1 (en) | 2008-12-31 |
JP2008526906A (ja) | 2008-07-24 |
ZA200704728B (en) | 2008-07-30 |
EP1838315B1 (de) | 2014-03-12 |
MY142493A (en) | 2010-11-30 |
MX2007008269A (es) | 2008-01-16 |
BRPI0519854A2 (pt) | 2009-03-24 |
WO2006074813A1 (de) | 2006-07-20 |
DK1838315T3 (da) | 2014-06-16 |
NO20074084L (no) | 2007-09-28 |
DOP2006000011A (es) | 2006-07-15 |
NI200700162A (es) | 2008-04-21 |
CR9191A (es) | 2007-10-04 |
KR20070094916A (ko) | 2007-09-27 |
TW200637842A (en) | 2006-11-01 |
AU2005324833A1 (en) | 2006-07-20 |
US20080058328A1 (en) | 2008-03-06 |
PA8659501A1 (es) | 2006-09-08 |
RU2398766C2 (ru) | 2010-09-10 |
US7868003B2 (en) | 2011-01-11 |
CN101184488A (zh) | 2008-05-21 |
IL184314A0 (en) | 2007-10-31 |
NZ556080A (en) | 2009-08-28 |
UA88941C2 (ru) | 2009-12-10 |
EP1838315A1 (de) | 2007-10-03 |
PT1838315E (pt) | 2014-05-26 |
ES2470980T3 (es) | 2014-06-24 |
DE102005001411A1 (de) | 2006-07-27 |
CA2594419A1 (en) | 2006-07-20 |
MA29227B1 (fr) | 2008-02-01 |
UY29333A1 (es) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053326A1 (es) | 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. | |
AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
NO20073325L (no) | Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
AR081337A1 (es) | Derivados de 1,4-benzotiazepinas, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de trastornos metabolicos | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
AR062221A1 (es) | Imidazolidina-2,4- dionas sustituidas con arilaminoarilalquilo, medicamentos que comprenden estos compuestos y su uso | |
AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
AR055344A1 (es) | Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38 | |
AR074583A1 (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
RS51190B (sr) | Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti | |
AR043741A1 (es) | 4-feniltetrahidroisoquinoleinas sustituidas, su uso como un medicamento, y el medicamento que las comprende | |
AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
AR034700A1 (es) | Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentos | |
AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |